VANCOUVER, BC - The gene therapy market is expected to climb toward $36.55 billion by 2032 due to the increased demand for treatments that target genetic diseases, according to Equity Insider. In December 2025, the FDA approved three transformative cell therapies.
Cell and gene therapy is projected to reach $39.61 billion by 2034. The industry is growing at a rate of almost 18% each year.
The big players in the gene therapy market are Avant Technologies Inc., Vertex Pharmaceuticals Inc., CRISPR Therapeutics, Prime Medicine Inc., and Madrigal Pharmaceuticals Inc.
Avant is developing cell-based therapies for diabetes, aging, and chronic diseases using a technology that protects genetically modified therapeutic cells from immune rejection.
Vertex offered new data on therapy program for children ages 5-11 with severe sickle cell disease. According to Equity Insider, all four patients with sufficient follow-up achieved freedom from small vessel blockage for at least 12 months. In some cases, the treatment lasted for up to two years. Vertex is expecting to initiate global regulatory submissions for the 5-11 age group in 2026.
CRISPR is focusing on its ongoing clinical trial evaluating CTX310 which had positive date during phase one. “For the first time, we’ve shown that a single-course in vivo CRISPR treatment can safely and durably lower ANGPTL3, leading to clinically meaningful reductions in triglycerides and LDL,” Naimish Patel, M.D., CRISPR’s chief medical officer, stated.
Madrigal presented data that showed its treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients. The company also showed improvements across multiple imaging tests and biomarkers.
Prime announced positive results of treatments for chronic granulomatous disease. Demonstrating the first in-human safety and efficacy of Prime Editing technology. The patients remained free of CGD-related complications, with one stopping mesalamine treatment without disease flare.
The five companies have demonstrated extensive research and positive results in the gene therapy market.